Form 4: Jazz Pharmaceuticals' President & COO, Renee D. Gala, Reports Stock Grants
SEC Form 4
Renee D. Gala, President & COO of Jazz Pharmaceuticals, reports the acquisition of restricted stock units under the company's 2011 Equity Incentive Plan.
Summary
- On February 27, 2025, Renee D. Gala, President & COO of Jazz Pharmaceuticals, reported the acquisition of restricted stock units.
- These units were granted under the Issuer's 2011 Equity Incentive Plan.
- 23,111 restricted stock units vest in equal annual installments over four years, starting March 5, 2025.
- 11,555 restricted stock units will vest in full on June 30, 2026.
- Each restricted stock unit represents a contingent right to receive one ordinary share upon vesting.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive event.
Positives
- The granting of restricted stock units to the President & COO aligns her interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the restricted stock units.
Industry Context
Stock grants are a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock grants are a typical component of executive compensation packages in the pharmaceutical industry, aligning executive interests with shareholder value.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize equity-based compensation to incentivize their leadership teams.
- The vesting schedules described are fairly standard, with multi-year vesting periods being common to encourage long-term commitment.
Stakeholder Impact
- Shareholders may view the stock grant as a positive incentive for the President & COO to drive long-term value.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Transaction date for the acquisition of restricted stock units. |
| 03/03/2025 | Date of signature for the Form 4 filing. |
| 03/05/2025 | Vesting commencement date for 23,111 restricted stock units. |
| 06/30/2026 | Full vesting date for 11,555 restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.